Second, there are TNF family inhibitors with anti-cancer activity currently on the market: (a) Anthera Pharmaceuticals' Blisibimod - is a selective antagonist of B-cell activating factor (BAFF, also known as B-lymphocyte stimulator or BLyS), (b) Eli Lilly's LY2127399, a human monoclonal antibody that neutralizes B-cell activating factor (BAFF), for use in combination with bortezomib in patients with previously-treated multiple myeloma. The gene discussed is TNFSF13B; the disease is plasma cell myeloma.